USPTO serial 97196369
SUPERDONOR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 5, 2023
- Examiner
- SHOOR, AMIT KUMAR
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SUPERDONOR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Yael Rouach Cabilly
Yael Rouach Cabilly CABILLY & CO.6 MASKIT STREET, P.O. BOX 12352HERZLIYA, 4673300ISRAELGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Dietary supplements; food supplements; nutritional supplements; dietary and nutritional supplements; dietary food supplemental drinks; dietary food supplements; dietary supplement drink mixes in the nature of vitamin and mineral beverages; dietary supplements for animals; dietary supplements for human consumption; dietary supplements with a cosmetic effect; powdered food supplements; powdered nutritional supplements; probiotic supplements; probiotic dietary supplements; probiotic preparations for medical use; sedatives; antifungal medication in the nature of antifungal preparations; medicines for alleviating constipation; pharmaceutical preparations for treating allergies; pharmaceutical preparations for the treatment of hormonal disorders; medicines for treating intestinal disorders; preparations for treating colds; burn relief medication; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical antitussive-cold preparations; non-prescription medicines, namely, medicinal preparations in the nature of pills, tablets, capsules, caplets, liquid drops, sachets, oral liquids, suspensions, liquids, semi-solids, creams, syrups, ointments, lotions, gels, sprays, emulations, oils, pessaries, suppositories, granules and films for the treatment of cardiovascular disorders, antibiotic associated diarrhea, gastrointestinal disorders, neurological disorders, ophthalmological disorders, neurodegenerative disorders, cognitive impairment, damaged skin and tissue, pulmonary disorders, for supporting oncology treatments, for the prevention and treatment of allergies, for the prevention and treatment of bacterial vaginosis and vaginal related women health disorders, for the prevention and treatment of urogenital related health disorders, for alleviating constipation, for the prevention and treatment of dysbiosis, for enrichment of beneficial bacteria; medicines for dental purposes; medicines for veterinary purposes namely, anti-infective products for veterinary use, veterinary pharmaceutical preparations and substances for the treatment of cardiovascular disorders, antibiotic associated diarrhea, gastrointestinal disorders, neurological disorders, ophthalmological disorders, neurodegenerative disorders, cognitive impairment, damaged skin and tissue, pulmonary disorders, for supporting oncology treatments, for the prevention and treatment of allergies, for the prevention and treatment of vaginal related health disorders, for the prevention and treatment of urogenital related health disorders, for alleviating constipation, for the prevention and treatment of dysbiosis, for enrichment of beneficial bacteria; pain relief medication; decongestant capsules; herbal medicines, namely, medicinal herbal preparations, herbal pharmaceutical preparations and herbal substances for the treatment of cardiovascular disorders, antibiotic associated diarrhea, gastrointestinal disorders, neurological disorders, ophthalmological disorders, neurodegenerative disorders, cognitive impairment, damaged skin and tissue, pulmonary disorders, for supporting oncology treatments, for the prevention and treatment of allergies, for the prevention and treatment of vaginal related health disorders, for the prevention and treatment of urogenital related health disorders, for alleviating constipation, for the prevention and treatment of dysbiosis, for enrichment of beneficial bacteria; antihypertensives; antitussives; diarrhea medication; antiflatulants ; antiemetics; antivirals; pharmaceutical preparations for the treatment of allergic rhinitis; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations and substances for the treatment of damaged skin and tissue; medicines for treating gastrointestinal diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 5, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 5, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 20, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 20, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 31, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 15, 2023 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| May 12, 2023 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| May 9, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 10, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 9, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 9, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 21, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 11, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 11, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 11, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 6, 2022 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jan 5, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 3, 2022 | NWAP | NEW APPLICATION ENTERED | — |